
Carlsmed Inc (CARL) Stock Forecast & Price Target
Carlsmed Inc (CARL) Analyst Ratings
Bulls say
Carlsmed is expected to continue growing and reaching profitability, with a Buy rating and positive outlook due to their unique technology, favorable clinical outcomes, and experienced leadership team. Despite potential risks in the form of competition and reimbursement, the company has shown strong financial results and is targeting a large global market with a hybrid sales model. However, it's important to monitor potential risks, such as their concentrated customer base, as the company continues to expand and grow.
Bears say
Carlsmed is a commercial-stage company with a limited product portfolio and relatively low revenue growth forecasted for the next few years, making it less attractive for potential investors. This, combined with the company's slow progress towards achieving profitability and potential challenges in achieving cash flow breakeven on < $200 million in revenue, could contribute to a negative outlook on the stock. Additionally, while management expects significant revenue growth and multiple product launches, there are potential risks and uncertainties in achieving these targets.
This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.
Carlsmed Inc (CARL) Analyst Forecast & Price Prediction
Start investing in Carlsmed Inc (CARL)
Order type
Buy in
Order amount
Est. shares
0 shares